Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term weight effects of rimonabant 10 mg vs 20 mg after initial 6-month 20 mg treatment in overweight/obese patients
2007-002492-14Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rimonabant in obesity, Overweight, type 2 diabetes mellitus (T2DM) and 1 more (2 arms), sponsored by Sanofi. Primary endpoint: Absolute change in body weight at 12 months. Started Jan 2008; status: completed.
02
Drugs
rimonabant
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on 2007-002492-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002492-14.